Concepts (180)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Thyroid Neoplasms | 11 | 2022 | 39 | 2.120 |
Why?
|
| Pathology | 3 | 2021 | 8 | 1.300 |
Why?
|
| Brain Neoplasms | 4 | 2018 | 313 | 1.290 |
Why?
|
| Proto-Oncogene Proteins B-raf | 5 | 2022 | 33 | 1.280 |
Why?
|
| Biomarkers, Tumor | 7 | 2022 | 415 | 1.230 |
Why?
|
| Pathology, Surgical | 3 | 2015 | 4 | 1.220 |
Why?
|
| Telomerase | 3 | 2017 | 38 | 1.190 |
Why?
|
| Glioma | 3 | 2018 | 122 | 1.090 |
Why?
|
| Telepathology | 3 | 2016 | 4 | 1.080 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2020 | 105 | 0.970 |
Why?
|
| Teratoma | 2 | 2022 | 17 | 0.930 |
Why?
|
| Melanoma | 3 | 2014 | 140 | 0.860 |
Why?
|
| Lung Neoplasms | 2 | 2020 | 360 | 0.810 |
Why?
|
| Pathology, Clinical | 3 | 2014 | 11 | 0.800 |
Why?
|
| Carcinoma, Papillary | 4 | 2022 | 18 | 0.790 |
Why?
|
| Diagnostic Errors | 2 | 2014 | 32 | 0.780 |
Why?
|
| Dermoid Cyst | 1 | 2022 | 2 | 0.760 |
Why?
|
| Carcinoma | 4 | 2018 | 74 | 0.730 |
Why?
|
| Isocitrate Dehydrogenase | 3 | 2021 | 20 | 0.720 |
Why?
|
| Humans | 41 | 2025 | 28983 | 0.700 |
Why?
|
| User-Computer Interface | 1 | 2021 | 58 | 0.670 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2020 | 97 | 0.640 |
Why?
|
| Prognosis | 9 | 2021 | 812 | 0.630 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2020 | 140 | 0.620 |
Why?
|
| Laboratories | 3 | 2014 | 18 | 0.600 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2020 | 166 | 0.600 |
Why?
|
| Electronic Health Records | 2 | 2010 | 66 | 0.590 |
Why?
|
| Ovarian Neoplasms | 2 | 2022 | 607 | 0.560 |
Why?
|
| Biopsy, Fine-Needle | 2 | 2020 | 24 | 0.510 |
Why?
|
| Thyroid Nodule | 3 | 2021 | 8 | 0.500 |
Why?
|
| Fibroma | 1 | 2016 | 6 | 0.490 |
Why?
|
| Bone Neoplasms | 1 | 2016 | 31 | 0.480 |
Why?
|
| Periodicals as Topic | 1 | 2016 | 53 | 0.470 |
Why?
|
| Neoplasm Metastasis | 3 | 2018 | 164 | 0.460 |
Why?
|
| Skin Neoplasms | 2 | 2013 | 147 | 0.450 |
Why?
|
| Medical Informatics | 1 | 2015 | 13 | 0.450 |
Why?
|
| Receptors, Nerve Growth Factor | 1 | 2014 | 3 | 0.450 |
Why?
|
| Liver Neoplasms | 2 | 2022 | 167 | 0.450 |
Why?
|
| Mutation | 6 | 2022 | 868 | 0.440 |
Why?
|
| Smartphone | 1 | 2015 | 80 | 0.440 |
Why?
|
| Uncertainty | 1 | 2014 | 25 | 0.430 |
Why?
|
| Curriculum | 2 | 2015 | 307 | 0.410 |
Why?
|
| Nerve Tissue Proteins | 1 | 2014 | 154 | 0.410 |
Why?
|
| Neoplastic Stem Cells | 1 | 2014 | 141 | 0.400 |
Why?
|
| Molecular Diagnostic Techniques | 2 | 2020 | 21 | 0.390 |
Why?
|
| Solitary Fibrous Tumors | 1 | 2012 | 3 | 0.380 |
Why?
|
| Practice Guidelines as Topic | 1 | 2014 | 249 | 0.370 |
Why?
|
| Communication | 1 | 2014 | 184 | 0.370 |
Why?
|
| Female | 15 | 2022 | 15682 | 0.360 |
Why?
|
| Gallbladder Neoplasms | 1 | 2012 | 14 | 0.360 |
Why?
|
| Promoter Regions, Genetic | 3 | 2017 | 344 | 0.360 |
Why?
|
| Cytodiagnosis | 1 | 2011 | 12 | 0.360 |
Why?
|
| Hemangioendothelioma | 1 | 2010 | 1 | 0.330 |
Why?
|
| Male | 13 | 2021 | 13978 | 0.330 |
Why?
|
| Medical Records | 1 | 2010 | 52 | 0.330 |
Why?
|
| Checklist | 1 | 2010 | 22 | 0.330 |
Why?
|
| Curcumin | 1 | 2010 | 69 | 0.310 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2012 | 481 | 0.300 |
Why?
|
| Diagnosis, Differential | 4 | 2016 | 379 | 0.300 |
Why?
|
| Forms and Records Control | 1 | 2009 | 6 | 0.300 |
Why?
|
| Adenocarcinoma, Follicular | 2 | 2022 | 4 | 0.270 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2012 | 843 | 0.270 |
Why?
|
| Aged, 80 and over | 5 | 2021 | 2065 | 0.260 |
Why?
|
| Registries | 1 | 2009 | 398 | 0.250 |
Why?
|
| Aged | 7 | 2021 | 5606 | 0.250 |
Why?
|
| Cooperative Behavior | 1 | 2006 | 78 | 0.240 |
Why?
|
| Quality Assurance, Health Care | 1 | 2006 | 64 | 0.240 |
Why?
|
| Pancreatic Neoplasms | 1 | 2012 | 548 | 0.240 |
Why?
|
| Laboratories, Hospital | 1 | 2025 | 1 | 0.230 |
Why?
|
| Immunohistochemistry | 4 | 2014 | 465 | 0.230 |
Why?
|
| Accreditation | 1 | 2025 | 37 | 0.230 |
Why?
|
| Rural Population | 1 | 2006 | 137 | 0.220 |
Why?
|
| Thyroid Gland | 2 | 2022 | 32 | 0.220 |
Why?
|
| Adult | 7 | 2021 | 8045 | 0.200 |
Why?
|
| Incidence | 2 | 2016 | 573 | 0.200 |
Why?
|
| United States | 5 | 2015 | 2246 | 0.200 |
Why?
|
| Carcinoma, Mucoepidermoid | 1 | 2022 | 9 | 0.190 |
Why?
|
| Eosinophilia | 1 | 2022 | 8 | 0.190 |
Why?
|
| Clinical Laboratory Information Systems | 2 | 2015 | 2 | 0.190 |
Why?
|
| Thyroid Carcinoma, Anaplastic | 1 | 2021 | 2 | 0.180 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2022 | 120 | 0.180 |
Why?
|
| Immunoblastic Lymphadenopathy | 1 | 2021 | 2 | 0.170 |
Why?
|
| Lymphoma, T-Cell | 1 | 2021 | 8 | 0.170 |
Why?
|
| rhoA GTP-Binding Protein | 1 | 2021 | 33 | 0.170 |
Why?
|
| Middle Aged | 5 | 2021 | 7425 | 0.170 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2022 | 133 | 0.160 |
Why?
|
| Retrospective Studies | 3 | 2021 | 2644 | 0.160 |
Why?
|
| Neoplasm Invasiveness | 3 | 2018 | 190 | 0.150 |
Why?
|
| Neoplasms | 1 | 2009 | 875 | 0.150 |
Why?
|
| Genetic Markers | 1 | 2018 | 92 | 0.140 |
Why?
|
| Gene Expression Profiling | 1 | 2020 | 465 | 0.140 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2017 | 347 | 0.130 |
Why?
|
| Internship and Residency | 3 | 2016 | 263 | 0.130 |
Why?
|
| Neoplasm Grading | 1 | 2017 | 105 | 0.130 |
Why?
|
| Societies, Medical | 3 | 2014 | 93 | 0.130 |
Why?
|
| Databases, Factual | 4 | 2021 | 271 | 0.130 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 236 | 0.130 |
Why?
|
| Sclerosis | 1 | 2016 | 3 | 0.120 |
Why?
|
| Incidental Findings | 1 | 2016 | 13 | 0.120 |
Why?
|
| Clinical Competence | 2 | 2015 | 245 | 0.120 |
Why?
|
| Neovascularization, Pathologic | 1 | 2017 | 148 | 0.120 |
Why?
|
| Workflow | 1 | 2016 | 25 | 0.120 |
Why?
|
| False Positive Reactions | 2 | 2012 | 31 | 0.120 |
Why?
|
| Lipoma | 1 | 2016 | 11 | 0.120 |
Why?
|
| Age of Onset | 1 | 2016 | 72 | 0.120 |
Why?
|
| Survival Rate | 1 | 2017 | 433 | 0.120 |
Why?
|
| CA-125 Antigen | 1 | 1996 | 19 | 0.120 |
Why?
|
| Specimen Handling | 1 | 2016 | 33 | 0.120 |
Why?
|
| Calcinosis | 1 | 2016 | 25 | 0.120 |
Why?
|
| Video Recording | 1 | 2015 | 41 | 0.120 |
Why?
|
| Combined Modality Therapy | 1 | 2016 | 303 | 0.110 |
Why?
|
| Risk Assessment | 1 | 2017 | 631 | 0.110 |
Why?
|
| Problem-Based Learning | 1 | 2015 | 62 | 0.110 |
Why?
|
| Sex Factors | 1 | 2016 | 470 | 0.110 |
Why?
|
| Translocation, Genetic | 1 | 2014 | 23 | 0.110 |
Why?
|
| Chromosomes, Human, X | 1 | 2014 | 38 | 0.110 |
Why?
|
| Melanoma-Specific Antigens | 1 | 2013 | 2 | 0.100 |
Why?
|
| gp100 Melanoma Antigen | 1 | 2013 | 2 | 0.100 |
Why?
|
| MART-1 Antigen | 1 | 2013 | 3 | 0.100 |
Why?
|
| Monophenol Monooxygenase | 1 | 2013 | 6 | 0.100 |
Why?
|
| S100 Proteins | 1 | 2013 | 6 | 0.100 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2013 | 21 | 0.100 |
Why?
|
| Microphthalmia-Associated Transcription Factor | 1 | 2013 | 7 | 0.100 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2014 | 79 | 0.100 |
Why?
|
| Kidney Neoplasms | 1 | 2014 | 103 | 0.100 |
Why?
|
| Infant | 2 | 2021 | 1049 | 0.100 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2012 | 6 | 0.090 |
Why?
|
| False Negative Reactions | 1 | 2012 | 24 | 0.090 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2012 | 42 | 0.090 |
Why?
|
| Young Adult | 2 | 2021 | 2842 | 0.090 |
Why?
|
| Computer-Assisted Instruction | 1 | 2012 | 33 | 0.090 |
Why?
|
| Oklahoma | 2 | 2012 | 1058 | 0.090 |
Why?
|
| Risk | 1 | 2011 | 138 | 0.090 |
Why?
|
| Biopsy | 1 | 2012 | 208 | 0.090 |
Why?
|
| Education, Medical | 1 | 2012 | 68 | 0.090 |
Why?
|
| Early Detection of Cancer | 1 | 2012 | 137 | 0.080 |
Why?
|
| Remission Induction | 1 | 2010 | 58 | 0.080 |
Why?
|
| Predictive Value of Tests | 1 | 2012 | 485 | 0.080 |
Why?
|
| Diagnostic Imaging | 1 | 2010 | 70 | 0.080 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2010 | 79 | 0.080 |
Why?
|
| Gene Rearrangement | 2 | 2022 | 15 | 0.080 |
Why?
|
| Systematized Nomenclature of Medicine | 1 | 2009 | 1 | 0.070 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2022 | 75 | 0.070 |
Why?
|
| Treatment Outcome | 2 | 2014 | 2427 | 0.070 |
Why?
|
| Dietary Supplements | 1 | 2010 | 273 | 0.070 |
Why?
|
| Lymphatic Metastasis | 2 | 2018 | 126 | 0.070 |
Why?
|
| Quality Control | 1 | 2025 | 21 | 0.060 |
Why?
|
| Vietnam | 1 | 2025 | 46 | 0.060 |
Why?
|
| Developing Countries | 1 | 2025 | 49 | 0.060 |
Why?
|
| Hospitals | 1 | 2025 | 77 | 0.060 |
Why?
|
| Antineoplastic Agents | 1 | 2010 | 686 | 0.050 |
Why?
|
| Oncogenes | 1 | 2022 | 34 | 0.050 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2022 | 51 | 0.050 |
Why?
|
| Adolescent | 2 | 2021 | 3223 | 0.040 |
Why?
|
| Dioxygenases | 1 | 2021 | 8 | 0.040 |
Why?
|
| Publication Bias | 1 | 2021 | 11 | 0.040 |
Why?
|
| Asia | 1 | 2020 | 20 | 0.040 |
Why?
|
| Epigenesis, Genetic | 1 | 2021 | 148 | 0.040 |
Why?
|
| Transcription Factors | 1 | 2022 | 523 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2020 | 524 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2021 | 472 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2018 | 237 | 0.030 |
Why?
|
| ras Proteins | 1 | 2017 | 43 | 0.030 |
Why?
|
| DNA-Binding Proteins | 1 | 2021 | 490 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2021 | 1196 | 0.030 |
Why?
|
| Models, Statistical | 1 | 2018 | 128 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2017 | 288 | 0.030 |
Why?
|
| Hypereosinophilic Syndrome | 1 | 1996 | 3 | 0.030 |
Why?
|
| Health Services Misuse | 1 | 1996 | 3 | 0.030 |
Why?
|
| Child | 1 | 2021 | 2327 | 0.030 |
Why?
|
| Melanins | 1 | 2014 | 6 | 0.030 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2014 | 15 | 0.030 |
Why?
|
| Nephrectomy | 1 | 2014 | 48 | 0.030 |
Why?
|
| Leadership | 1 | 2014 | 55 | 0.030 |
Why?
|
| Risk Factors | 1 | 2018 | 2133 | 0.020 |
Why?
|
| Phenotype | 1 | 2014 | 686 | 0.020 |
Why?
|
| Internet | 1 | 2012 | 127 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2014 | 676 | 0.020 |
Why?
|
| Students, Medical | 1 | 2012 | 102 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2012 | 788 | 0.020 |
Why?
|